Latest Videos |view all videos
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Alan P. Fields, Ph.D., and Dr. Monica Flynn Jacoby, professor of cancer studies at Mayo Clinic's campus in Florida, talk about the publication of his team's latest discovery.
A study published today in the journal BMJ says annual screening mammograms in women ages 40 to 59 do not reduce deaths from breast cancer any better than a physical examination or usual care.
Judy C. Boughey, M.D., and Matthew P. Goetz, M.D., present Breast Cancer Genome-Guided Therapy Study: Next-Generation Sequencing for the Management of Women With High-Risk Breast Cancer.
Panagiotis Z. Anastasiadis, Ph.D., presents Targeting Polarity Pathways for Cancer Treatment.
Newly diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo ...
Blacks may be twice as likely as whites to develop multiple myeloma because they are also more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
With the glut of data generated through next-generation sequencing, interpretation has become the new bottleneck in scientific discovery and clinical application.
A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk of poorer survival rate following prostate cancer treatment compared with other minority groups.
Unique laboratory testing during breast cancer lumpectomies to make sure surgeons removed all the cancerous tissue spares patients the need for a repeat operation in roughly 96 percent of cases at Mayo Clinic in Rochester, Minnesota.
A clinical trial co-led by Mayo Clinic Cancer Center researchers found that adding chemotherapy following radiation treatment improved survival for adults with low-grade gliomas by more than five years.
Needle-guided tumor destruction procedures offer near-equivalent lengths of local cancer control compared with surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology.